NPPNY OTC
Nippon Shinyaku Co., Ltd.
1W: -1.1%
1M: -6.1%
3M: -10.0%
YTD: -38.5%
1Y: +3.2%
3Y: -48.1%
5Y: -66.5%
$5.40
-0.06 (-1.10%)
Weekly Expected Move ±7.5%
$5
$5
$5
$6
$6
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.5B
52W Range5.0275-15.21
Volume2,509
Avg Volume59
Beta-0.32
Dividend$0.20
Analyst Ratings
No analyst coverage
Company Info
CEOToru Nakai
Employees2,309
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2016-11-16
Websitenippon-shinyaku.co.jp
14, Nishinosho-Monguchi-cho
Kyoto, KY 601-8550
JP
Kyoto, KY 601-8550
JP
81 7 5321 1111
About Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Latest News
Nippon Shinyaku Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation (OTCMKTS:NPPNY) 2026-08-10 - Seeking Alpha
NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
Recent Insider Trades
No insider trades found